Jaffer A Ajani, Thomas A D'Amico, David J Bentrem, Carlos U Corvera, Prajnan Das, Peter C Enzinger, Thomas Enzler, Hans Gerdes, Michael K Gibson, Patrick Grierson, Garima Gupta, Wayne L Hofstetter, David H Ilson, Shadia Jalal, Sunnie Kim, Lawrence R Kleinberg, Samuel Klempner, Jill Lacy, Byrne Lee, Frank Licciardi, Shane Lloyd, Quan P Ly, Karen Matsukuma, Michael McNamara, Ryan P Merkow, Aaron M Miller, Sarbajit Mukherjee, Mary F Mulcahy, Kyle A Perry, Jose M Pimiento, Deepti M Reddi, Scott Reznik, Robert E Roses, Vivian E Strong, Stacey Su, Nataliya Uboha, Zev A Wainberg, Christopher G Willett, Yanghee Woo, Harry H Yoon, Nicole R McMillian, MaryElizabeth Stein
{"title":"Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.","authors":"Jaffer A Ajani, Thomas A D'Amico, David J Bentrem, Carlos U Corvera, Prajnan Das, Peter C Enzinger, Thomas Enzler, Hans Gerdes, Michael K Gibson, Patrick Grierson, Garima Gupta, Wayne L Hofstetter, David H Ilson, Shadia Jalal, Sunnie Kim, Lawrence R Kleinberg, Samuel Klempner, Jill Lacy, Byrne Lee, Frank Licciardi, Shane Lloyd, Quan P Ly, Karen Matsukuma, Michael McNamara, Ryan P Merkow, Aaron M Miller, Sarbajit Mukherjee, Mary F Mulcahy, Kyle A Perry, Jose M Pimiento, Deepti M Reddi, Scott Reznik, Robert E Roses, Vivian E Strong, Stacey Su, Nataliya Uboha, Zev A Wainberg, Christopher G Willett, Yanghee Woo, Harry H Yoon, Nicole R McMillian, MaryElizabeth Stein","doi":"10.6004/jnccn.2025.0022","DOIUrl":null,"url":null,"abstract":"<p><p>Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.</p>","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":"23 5","pages":"169-191"},"PeriodicalIF":14.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6004/jnccn.2025.0022","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.
期刊介绍：
JNCCN—Journal of the National Comprehensive Cancer Network is a peer-reviewed medical journal read by over 25,000 oncologists and cancer care professionals nationwide. This indexed publication delivers the latest insights into best clinical practices, oncology health services research, and translational medicine. Notably, JNCCN provides updates on the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), review articles elaborating on guideline recommendations, health services research, and case reports that spotlight molecular insights in patient care.
Guided by its vision, JNCCN seeks to advance the mission of NCCN by serving as the primary resource for information on NCCN Guidelines®, innovation in translational medicine, and scientific studies related to oncology health services research. This encompasses quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship.
JNCCN boasts indexing by prominent databases such as MEDLINE/PubMed, Chemical Abstracts, Embase, EmCare, and Scopus, reinforcing its standing as a reputable source for comprehensive information in the field of oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
